Adding arabinosylcytosine to idarubicin induction therapy may not improve survival for people with newly diagnosed acute promyelocytic leukaemia.
Estey
Elihu
E
Acute Leukemias and MDS, University of Texas MD, Anderson Cancer Center, Houston, Texas, USA. eheestey@mdanderson.org <eheestey@mdanderson.org>
Sanz
Miguel A
MA